Wanbury profit and loss

Latest FY26
Revenue
₹650cr+8.5% on FY25
EBITDA
₹107cr+39.9% on FY25
Net profit
₹66.1cr+116.6% on FY25
EPS
₹20.55+120.5% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
653650600576500
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.90.93.53.00.9
654651603579501
Expenses
274273278289257
16.216.615.117.316.0
−10.1−13.01.5−3.929.1
12612010486.981.0
30.430.037.029.221.4
14.714.313.313.012.4
14814712411692.9
599588573548510
98.610776.370.023.2
83.892.463.057.010.8
Profit
54.463.429.630.8−9.7
−3.6−3.60.00.0−0.6
50.859.829.630.8−10.3
0.60.65.90.00.0
−5.7−7.0−6.80.40.1
−5.1−6.3−1.00.40.1
0.00.00.00.00.0
55.966.130.530.4−10.4
55.966.130.530.4−10.4
−0.5−0.5−0.4−0.70.1
55.465.630.229.7−10.3
Per share
₹17.36₹20.55₹9.32₹9.29−₹6.18
₹16.35₹19.49₹8.98₹9.18−₹6.18
Other comprehensive income — detail
−0.5−0.5−0.4——
−0.7−0.7−0.5−1.10.1
−0.1−0.2−0.2——
———−0.40.0
—0.0−0.0——
0.00.0−0.0——
Per share — as-filed variants
₹17.36₹20.55₹9.32₹9.29−₹3.00
₹16.35₹19.49₹8.98₹9.18−₹3.00
₹0.00₹0.00₹0.00₹0.00−₹3.18
₹0.00₹0.00₹0.00₹0.00−₹3.18
Derived — gross profit (revenue − materials − purchases − Δ inventories)
373374305273197
57.1%57.5%50.9%47.4%39.4%
Adjusted (ex-exceptional items) — derived
54.463.429.630.8−9.7
−3.6−3.60.00.0−0.6
59.569.730.530.4−9.8
₹18.48₹21.67₹9.32₹9.29−₹5.83
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

WANBURY₹174.16

Wanbury Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersAHCLANUHPHRBAJAJHCARETHEMISMEDZIMLABLINCOLNSIGACHIVALIANTLABMcap ₹609 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations499.6575.6599.5650.3652.7
Other Income0.93.03.50.90.9
Total Income500.6578.6603.0651.2653.6
Expenses
+ Cost of Materials Consumed257.5289.2277.9272.9274.1
+ Purchases of Stock-in-Trade16.017.315.116.616.2
+ Changes in Inventories29.1-3.91.5-13.0-10.1
+ Employee Benefit Expense81.086.9104.2119.6126.3
+ Finance Costs21.429.237.030.030.4
+ Depreciation & Amortisation12.413.013.314.314.7
+ Other Expenses92.9116.1124.5147.4147.6
Total Expenses510.3547.9573.5587.8599.2
EBITDA23.270.076.3106.898.6
EBIT10.857.063.092.483.8
Profit
PBT before Exceptional Items-9.730.829.663.454.4
+ Exceptional Items-0.60.00.0-3.6-3.6
Pretax Income-10.330.829.659.850.8
+ Current Tax0.00.05.90.60.6
+ Deferred Tax0.10.4-6.8-7.0-5.7
Tax Expense0.10.4-1.0-6.3-5.1
+ Share of Associates & JVs0.00.00.00.00.0
Net Income-10.430.430.566.155.9
+ Net Income — Continuing Ops-10.430.430.566.155.9
+ Other Comprehensive Income0.1-0.7-0.4-0.5-0.5
Total Comprehensive Income-10.329.730.265.655.4
Per Share
Basic EPS-6.189.299.3220.5517.36
Diluted EPS-6.189.188.9819.4916.35
Other Comprehensive Income — detail
+ Other Comprehensive Income——-0.4-0.5-0.5
+ Items NOT to be Reclassified to P&L0.1-1.1-0.5-0.7-0.7
+ Tax on Items NOT to be Reclassified——-0.2-0.2-0.1
+ Tax on Items NOT to be Reclassified — alt tag0.0-0.4———
+ Items to be Reclassified to P&L——-0.00.0—
+ Tax on Items to be Reclassified——-0.00.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations-3.009.299.3220.5517.36
Diluted EPS — Continuing Operations-3.009.188.9819.4916.35
Basic EPS — Discontinued Operations-3.180.000.000.000.00
Diluted EPS — Discontinued Operations-3.180.000.000.000.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit197.1273.0305.0373.8372.5
Gross Margin %39.4447.4350.8857.4857.07
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)-9.730.829.663.454.4
− Exceptional Items (reconciliation)-0.60.00.0-3.6-3.6
Net Income Adj (tax-effected)-9.830.430.569.759.5
EPS Adj-5.839.299.3221.6718.48
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.00
Paid Up Equity Capital32.732.732.834.934.9
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.